Adverum Biotechnologies Inc (ADVM)

$2.25 -0.04 (-1.75%)
Market Cap 47.01M
Revenue (ttm) 1.00M
Net Income (ttm) -130.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13,093.00%
Debt to Equity Ratio 0.00
Volume 173,900
Avg Vol 383,710
Day's Range N/A - N/A
Shares Out 20.89M
Stochastic %K 4%
Beta 0.71
Analysts Strong Sell
Price Target $20.75

Company Profile

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a f...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 656 9323
Fax: 650 649 1995
Website: adverum.com
Address:
100 Cardinal Way, Redwood City, United States
alexx013
alexx013 Jun. 18 at 6:58 PM
$ADVM bought some more @ 2.23
0 · Reply
SecondChances
SecondChances Jun. 17 at 6:47 PM
$ADVM anyone knows what happened in today’s shareholders meeting?
2 · Reply
clockwatch2
clockwatch2 Jun. 13 at 3:25 PM
$ADVM someday
1 · Reply
socke2003
socke2003 Jun. 12 at 1:37 PM
$ADVM why we goes Down? Bad News???
1 · Reply
alexx013
alexx013 Jun. 10 at 2:33 PM
$ADVM 3 busted, next 4
0 · Reply
flinder1f7
flinder1f7 Jun. 10 at 2:31 PM
$ADVM any chart experts here, I would like to take some profit and reenter again
0 · Reply
alexx013
alexx013 Jun. 9 at 1:38 PM
$ADVM lets bust 3 today
0 · Reply
Kosmokrat
Kosmokrat Jun. 9 at 12:40 PM
Any idea on how $ADVM will raise cash to sustain operations throughout 2025 and beyond? Partner deal including upfront / milestone payments? Or a BO? Maybe strike a deal with Royalty Pharma, to bridge the gap of a successful phase 3 study and the first sales revenue? Or a diluting capital injection? What's your guess?
1 · Reply
alexx013
alexx013 Jun. 6 at 3:59 PM
$ADVM this will at least double by eoy
0 · Reply
builderup
builderup Jun. 6 at 3:13 PM
$ADVM Patience is key. 😊. Been waiting on this move. Let’s go
0 · Reply
Latest News on ADVM
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 5, 2025, 4:01 PM EDT - 17 days ago

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

May 14, 2025, 4:05 PM EDT - 5 weeks ago

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 30, 2025, 10:00 AM EDT - 7 weeks ago

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Shareholders to Inquire about Securities Investigation

Apr 29, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Shareholders to Connect

Apr 28, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation

Apr 25, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Adverum Biotechnologies, Inc. (ADVM) and Encourages Investors to Learn More About the Investigation

Apr 24, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Adverum Biotechnologies, Inc. (ADVM) and Encourages Investors to Learn More About the Investigation

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 23, 2025, 10:00 AM EDT - 2 months ago

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Connect

Apr 22, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation

Apr 20, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out

Apr 18, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out

Apr 17, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Connect

Apr 16, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Connect

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Apr 15, 2025, 12:00 PM EDT - 2 months ago

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm

Apr 15, 2025, 9:09 AM EDT - 2 months ago

ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 4, 2025, 4:05 PM EDT - 2 months ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 31, 2025, 4:01 PM EDT - 2 months ago

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Mar 3, 2025, 4:01 PM EST - 3 months ago

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

Feb 25, 2025, 7:00 AM EST - 4 months ago

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 4:05 PM EST - 4 months ago

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 20, 2024, 4:05 PM EST - 7 months ago

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Nov 18, 2024, 1:37 PM EST - 7 months ago

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Nov 15, 2024, 4:05 PM EST - 7 months ago

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Nov 4, 2024, 4:39 PM EST - 8 months ago

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Oct 16, 2024, 8:00 AM EDT - 8 months ago

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Sep 4, 2024, 4:05 PM EDT - 10 months ago

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 2, 2024, 7:00 AM EDT - 11 months ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript

Jul 17, 2024, 3:35 PM EDT - 1 year ago

Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Jul 17, 2024, 2:45 AM EDT - 1 year ago

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

May 9, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

May 3, 2024, 8:00 AM EDT - 1 year ago

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

Feb 8, 2024, 7:00 AM EST - 1 year ago

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

Feb 5, 2024, 7:45 AM EST - 1 year ago

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

Feb 1, 2024, 5:30 PM EST - 1 year ago

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

Jan 29, 2024, 8:00 AM EST - 1 year ago

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

Dec 7, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

Nov 28, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Nov 9, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Adverum Biotechnologies Appoints C. David Nicholson, Ph.D.

Nov 6, 2023, 8:00 AM EST - 1 year ago

Adverum Biotechnologies Appoints C. David Nicholson, Ph.D.

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

Nov 4, 2023, 5:54 PM EDT - 1 year ago

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial

Sep 26, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial

alexx013
alexx013 Jun. 18 at 6:58 PM
$ADVM bought some more @ 2.23
0 · Reply
SecondChances
SecondChances Jun. 17 at 6:47 PM
$ADVM anyone knows what happened in today’s shareholders meeting?
2 · Reply
clockwatch2
clockwatch2 Jun. 13 at 3:25 PM
$ADVM someday
1 · Reply
socke2003
socke2003 Jun. 12 at 1:37 PM
$ADVM why we goes Down? Bad News???
1 · Reply
alexx013
alexx013 Jun. 10 at 2:33 PM
$ADVM 3 busted, next 4
0 · Reply
flinder1f7
flinder1f7 Jun. 10 at 2:31 PM
$ADVM any chart experts here, I would like to take some profit and reenter again
0 · Reply
alexx013
alexx013 Jun. 9 at 1:38 PM
$ADVM lets bust 3 today
0 · Reply
Kosmokrat
Kosmokrat Jun. 9 at 12:40 PM
Any idea on how $ADVM will raise cash to sustain operations throughout 2025 and beyond? Partner deal including upfront / milestone payments? Or a BO? Maybe strike a deal with Royalty Pharma, to bridge the gap of a successful phase 3 study and the first sales revenue? Or a diluting capital injection? What's your guess?
1 · Reply
alexx013
alexx013 Jun. 6 at 3:59 PM
$ADVM this will at least double by eoy
0 · Reply
builderup
builderup Jun. 6 at 3:13 PM
$ADVM Patience is key. 😊. Been waiting on this move. Let’s go
0 · Reply
DorthaSealock226
DorthaSealock226 Jun. 6 at 3:11 PM
$ADVM is flying under the radar but ZBAO is flashing clear breakout signals.
0 · Reply
builderup
builderup Jun. 6 at 2:52 PM
Whatever I buy I’m willing to hold for 90 days. Call it swing trading or position or whatever. Looking back at this post I was a little cautious with my predictions. Nailed it. Not saying I hit it everytime but not bad. $CTMX $OMI $RLAY $ADVM
0 · Reply
dthekang
dthekang Jun. 5 at 1:58 PM
$ADVM fallin fast and steady LOl
0 · Reply
builderup
builderup Jun. 2 at 7:40 PM
Research, Buy, Hold and Profit! $INTS - here we go $ADVM- nice and steady
0 · Reply
BioTechHealthX
BioTechHealthX May. 30 at 11:39 AM
$ADVM See the potential of Adverum as it develops Ixo-vec, a 1st-in-class intravitreal gene therapy for wet AMD w/ life-changing clinical benefits. https://biotechhealthx.com/biotech-news/adverum-biotechnologies-advm-is-the-future-of-vision-restoring-gene-therapy/
0 · Reply
shefgee
shefgee May. 29 at 6:19 PM
$ADVM
0 · Reply
dthekang
dthekang May. 27 at 5:44 PM
$ADVM what a big pos 🤮. Cash burner is right here.
0 · Reply
alexx013
alexx013 May. 19 at 5:33 PM
$ADVM north from here
0 · Reply
builderup
builderup May. 19 at 9:47 AM
$ADVM watching closely! $INTS 👀👀👀
0 · Reply
dthekang
dthekang May. 16 at 12:58 PM
$ADVM Sinking ship. Adios
1 · Reply
JarvisFlow
JarvisFlow May. 15 at 3:56 PM
RBC Capital updates rating for Adverum Biotechnologies ( $ADVM ) to Sector Perform, target set at 5 → 4.
0 · Reply
JarvisFlow
JarvisFlow May. 15 at 3:34 PM
Chardan Capital updates rating for Adverum Biotechnologies ( $ADVM ) to Buy, target set at 33.
0 · Reply